News

Read the latest news and views from Lymphoma Action. 

Use the drop down filter to find the most relevant news for you.

Text that says Results

Highlights from BSH

This year, the British Society for Haematology held their annual scientific meeting online. Clinical experts presented some of the latest developments across all areas of lymphoma research.

5 July 2021
SMC logo

Scotland approves two new treatments for use on the NHS

Mogamulizumab has been approved for people with rare types of relapsed or refractory skin lymphoma, and acalabrutinib has been approved as a first-line treatment for some people with chronic lymphocytic leukaemia (CLL).

7 June 2021
Scottish Medicines Consortium logo

Brentuximab vedotin

Brentuximab vedotin is to be available on the NHS in Scotland for first-line treatment of systemic anaplastic large cell lymphoma.

18 January 2021
ESMO logo

New guidelines on follicular lymphoma

New European guidelines give evidence-based recommendations for the diagnosis, treatment and follow-up of people with follicular lymphoma.

6 January 2021
ESMO logo

New guidelines on CLL

New European guidelines give evidence-based recommendations for the diagnosis, treatment and follow-up of people with CLL.

4 November 2020
SMC logo

New treatment options for lymphoma in Scotland

Lenalidomide plus rituximab is now available on the NHS in Scotland for relapsed or refractory follicular lymphoma, while ibrutinib has been approved for NHS use in people with relapsed or refractory Waldenström’s macroglobulinaemia.

20 October 2020
NICE logo

NICE approves new treatment for DLBCL

The National Institutes for Health and Care Excellence (NICE) has approved polatuzumab vedotin for use on the NHS in people with diffuse large B-cell lymphoma (DLBCL).

20 August 2020
NICE logo

Brentuximab vedotin

Brentuximab vedotin is to be available on the NHS for first-line treatment of anaplastic large cell lymphoma.

9 July 2020
European Medicines Agency logo

Brentuximab vedotin

The European Medicines Agency has approved brentuximab vedotin for first-line treatment of anaplastic large cell lymphoma.

22 April 2020
Diagram showing a T cell with a chimeric antigen receptor, with the activation signal meeting the stimulation signal attached to the antigen receptor

Improving access to CAR T-cell therapy

Lymphoma Action is continually pushing for improvements in the access to, and delivery of, CAR T-cell therapy to allow everybody who is suitable for treatment to access it.

12 August 2019
CAR T-cells

Behind the headline: Has CAR T-cell therapy got 'cancer on the run'?

It is true that CAR T-cells are a new type of treatment that could transform the prognosis for some people with difficult-to-treat lymphoma. However, it can have serious side effects and research is still ongoing to find out the long-term effects of the treatment.

21 June 2019
Talking to a nurse

Pembrolizumab for classical Hodgkin lymphoma

NICE/NHS England recommend pembrolizumab for people with relapsed or refractory Hodgkin lymphoma who have had brentuximab vedotin and cannot have an autologous stem cell transplant

2 August 2018
Two people talking about the new CLL guidelines

New CLL guidelines published

The British Society of Haematology have published their guidelines on the treatment of chronic lymphocytic leukaemia

24 July 2018
EHA Conference

Biosimilars in the real world

Stephen Scowcroft reports back from a biosimilars panel at the European Haematology Association (EHA) Congress 2018. 

25 June 2018